PARIS: L’Oréal Group announced Monday that it has signed an agreement to acquire a majority stake in British skincare brand Medik8, which will join its Luxe Division.
According to a statement, Private equity firm Inflexion will retain a minority stake in Medik8, while founder Elliot Isaacs will remain on the board. The current management team will also stay in place to ensure continuity.
Founded by Isaacs, a scientist, Medik8 is known for its Crystal Retinal serum and its “CSA Philosophy” — combining vitamin C and sunscreen during the day and vitamin A at night. The brand focuses on science-backed, premium skincare and is sold through online and offline retailers in Europe and the U.S.
The acquisition strengthens L’Oréal’s luxury skincare portfolio, adding a brand with a strong growth potential.
“We are delighted to welcome Medik8 to the L’Oréal family,” said Cyril Chapuy, president of L’Oréal Luxe. “With its proven efficacy and accessible pricing, Medik8 complements our skincare portfolio, and we believe in its global potential.”
Simon Coble, CEO of Medik8, called the deal “an exciting day” for the brand. “L’Oréal shares our vision for growth and commitment to science and innovation,” he said.
L’Oréal will begin consolidating Medik8’s sales once the deal closes. The company also secured rights to buy out remaining minority shareholders.
The transaction is expected to finalize in the coming months pending regulatory approvals.